Skip to main content
padlock icon - secure page this page is secure

Current Development of ROS-Modulating Agents as Novel Antitumor Therapy

Buy Article:

$68.00 + tax (Refund Policy)

Compared to normal cells, usually cancer cells are under higher oxidative stress. Elevating intracellular levels of reactive oxygen species (ROS) by introducing excessive ROS or inhibiting antioxidant system may enhance selectively of cancer cell killing by ROS-modulating agents through stress sensitization or stress overload. Meanwhile due to the adaptive response, normal cells may be capable of maintaining redox homeostasis under exogenous ROS. Here we review ROS-modulating agents in different mechanisms and classify them into groups by various targets for illustrating more clearly. At last, we discuss their side effects and the potential troubles of developing these agents and argue that might be an effective strategy for further exploring to modulate the unique redox regulatory mechanisms of cancer cells.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ROS-modulating agents; antioxidant system; antitumor therapy; exogenous generating ROS agents; mitochondrial respiratory chain; redox homeostasis

Document Type: Research Article

Publication date: February 1, 2017

More about this publication?
  • Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
    Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
    As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more